Trials / Completed
CompletedNCT01014585
Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia
A Multicenter, Randomized, Double-blind, Placebo-Controlled Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia in Patients Receiving Long-term Milnacipran Treatment
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 340 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the durability of effect of milnacipran for the treatment of fibromyalgia in patients receiving long-term milnacipran treatment and to characterize the effects of milnacipran on multiple symptoms of fibromyalgia, as demonstrated by changes in symptoms following the discontinuation of milnacipran.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo tablets administered orally twice daily |
| DRUG | Milnacipran | Milnacipran tablets administered orally twice daily |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-05-01
- First posted
- 2009-11-17
- Last updated
- 2011-09-07
- Results posted
- 2011-09-07
Locations
58 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01014585. Inclusion in this directory is not an endorsement.